Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
Randomized double-blind placebo-controlled crossover study design
Eligibility criteria
Qualifiers
Clinical diagnosis of heart failure
No plan for titration/change of heart failure medical or device therapies during the study period.
Absence of non-elective hospitalizations in the previous 2 months.
At optimal volume status by symptoms, exam, and dry weight.
Disqualifiers
Glomerular filtration rate (GFR) <20 ml/min/1.73m2
Use of any non-loop type diuretic in the last 7 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone ≤50 mg)
History of flash pulmonary edema or a "brittle" volume sensitive HF phenotype such as amyloid cardiomyopathy
Hemoglobin < 8 g/dL
Trial design
Treatments tested in this trial
- Ammonium Chloride
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Yale University
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov